Kate co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market.
Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in companies in the UK, EU and US.
Over the course of the firm's >30 year history, SV investments have led to the launch of 26 novel drugs including 6 first in class therapeutics. Many of these investments were led by Kate.
In 2021 Kate was awarded a DBE in the Queen’s Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purposed of finding and manufacturing COVID-19 vaccines.
Outside of SV, Kate serves on the Board of the Francis Crick
Institute and ARIA. At weekends Kate spends time in Wales where she
rides horses and mountain bikes, grows vegetables and competes in bog
snorkelling competitions.
Academic credentials
First class degree, Biochemistry, University of Oxford; MBA, Harvard Business School (Baker Scholar)
